<DOC>
	<DOC>NCT00862979</DOC>
	<brief_summary>This study will assess whether a calcineurin inhibitor (CNI)-free regimen with everolimus and mycophenolic acid is associated with a better renal outcome as compared to the standard regimen containing cyclosporine A (which belongs to the class of CNIs) and everolimus; while both treatments are expected to be comparable with respect to efficacy.</brief_summary>
	<brief_title>A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients</brief_title>
	<detailed_description>This study will assess whether a calcineurin inhibitor (CNI)-free regimen with everolimus and mycophenolic acid is associated with a better renal outcome as compared to the standard regimen containing cyclosporine A (which belongs to the class of CNIs) and everolimus; while both treatments are expected to be comparable with respect to efficacy.</detailed_description>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Inclusion criteria: Heart transplantation, 3 months prior to enrollment Patients have to receive an immunosuppressive regimen with Sandimmun® Optoral, Certican® and corticosteroids Sufficient graft function Sufficient renal function Females capable of becoming pregnant must have a negative serum pregnancy test within 7 days prior to or at baseline, and are required to practice an approved method of birth control for the duration of the study and for a period of 6 weeks following discontinuation of study medication, even where there has been a history of infertility Exclusion criteria: Multiorgan recipients, retransplantation, or previous transplant with any other organ. Patients who are recipients of ABO incompatible transplants Cold ischemia time &gt;6 hours Historical or current peak PRA of &gt; 25% at time of transplantation Already existing antibodies against the HLAtype of the receiving transplant Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Heart Transplantation</keyword>
	<keyword>Cardiac Transplantation</keyword>
	<keyword>CNI-sparing</keyword>
	<keyword>renal function</keyword>
	<keyword>CNI</keyword>
	<keyword>Cyclosporine A</keyword>
	<keyword>Everolimus</keyword>
	<keyword>enteric coated mycophenolic acid</keyword>
</DOC>